Other Operating Income

Other operating income was comprised as follows:

Other Operating Income

 

 

2015

 

2016

 

 

€ million

 

€ million

2015 figures restated

Gains on retirements of noncurrent assets

 

137

 

66

Reversals of impairment losses on receivables

 

32

 

20

Reversals of unutilized provisions

 

25

 

131

Gains from derivatives

 

272

 

259

Miscellaneous operating income

 

643

 

422

Total

 

1,109

 

898

of which special items

 

336

 

115

Income from reversals of unutilized provisions include an amount of €104 million from the reversal of provisions for the Yasmin™/ YAZ™ litigation.

Miscellaneous operating income included a €32 million gain incurred by Bayer 04 Leverkusen Fußball GmbH from the sale of transfer rights and a payment of €32 million received from insurers (Covestro segment). A reimbursement payment relating to the termination of a contract accounted for income of €27 million (Covestro segment). In the Crop Science segment, milestone payments led to income of €21 million. In the Pharmaceuticals segment, a €14 million compensation payment was received in connection with the closure of the production site in Putuo, China. Income of €19 million resulted from the reimbursement of indirect taxes paid in previous years (Covestro segment). A €10 million gain was incurred on the sale of the BAYQUIK™ technology to Chemetics, Inc., Canada (Other segments).

In 2015, gains from retirements of noncurrent assets included an amount of €53 million from the sale of trademark rights for the Biovital™, Benerva™, Bactine™ and ProPlus™ brands (Consumer Health segment).

Miscellaneous operating income in 2015 included €314 million in claims against Dow AgroSciences LLC, United States, for damages and royalty payments resulting from the infringement of Bayer’s rights to the Liberty Link™ weed control system (Crop Science segment).